FDA
-
-
-
-
-
-
-
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
-
-
-
-
-
-
-
ALX Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
-
-
-
-
-
-
-
ALX Oncology (ALXO) Provides Corporate Update
-
-
-
-
-
-
-
ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
-
-
-
-
-
-
-
ALX Oncology (ALXO) Announces Evorpacept Clinical Program Updates
-
-
-
-
-
-
-
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Cancer and Gastroesophageal Junction Cancer
-
322,090 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

